The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world data evaluating the value of PET-CT for mediastinal staging in patients diagnosed with non-small cell lung cancer in an area with high prevalence of granulomatous diseases: The LACOG-0114 study.
 
Carlos Cezar Fritscher
No Relationships to Disclose
 
Mara Lise Zanini
No Relationships to Disclose
 
Eduardo Herz Berdichevski
No Relationships to Disclose
 
Eduardo Vilas
No Relationships to Disclose
 
Bruno Hochhegger
No Relationships to Disclose
 
Vinicius Duval da Silva
No Relationships to Disclose
 
José Antônio Figueiredo Pinto
No Relationships to Disclose
 
Leandro Genehr Fritscher
No Relationships to Disclose
 
Louise Hartmann
No Relationships to Disclose
 
Marcos Alba
No Relationships to Disclose
 
Guilherme Parisotto Sartori
No Relationships to Disclose
 
Cristina Matushita
No Relationships to Disclose
 
Arthur Vieira
No Relationships to Disclose
 
Vanessa Rezende Bortolotto
No Relationships to Disclose
 
Rayssa Ruszkowski do Amaral
No Relationships to Disclose
 
Facundo Zaffaroni
No Relationships to Disclose
 
Jeovany Martínez-Mesa
No Relationships to Disclose
 
Gustavo Werutsky
No Relationships to Disclose
 
Carlos H. Barrios
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Exelixis; GlaxoSmithKline; GlaxoSmithKline; ImClone Systems; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Marcio Debiasi
No Relationships to Disclose